Stocktoria
LIGAND PHARMACEUTICALS INC LGND
LIGAND PHARMACEUTICALS INC (LGND) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $268.1M at a 46.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-05-08 | RBC Capital | Outperform (main) |
| 2026-04-30 | HC Wainwright & Co. | Buy (main) |
| 2026-04-28 | RBC Capital | Outperform (main) |
| 2026-04-15 | Citigroup | Buy (main) |
| 2026-04-14 | HC Wainwright & Co. | Buy (main) |
| 2026-03-24 | Citigroup | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.509 |
| Retained earnings / assets | 0.39 |
| EBIT / assets | 0.026 |
| Equity / liabilities | 1.872 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LGND | LIGAND PHARMACEUTICALS INC | 4/9 | 6.75 | 48.9 | +60.4% |
| HROW | HARROW, INC. | 6/9 | 1.29 | — | +36.4% |
| ARVN | ARVINAS, INC. | 4/9 | -1.73 | — | -0.3% |
| SDGR | Schrodinger, Inc. | 4/9 | -0.33 | — | +23.3% |
| AUPH | Aurinia Pharmaceuticals Inc. | 5/9 | 5.18 | 7.7 | +20.4% |
| RCUS | Arcus Biosciences, Inc. | — | -0.75 | — | -4.3% |
| XERS | Xeris Biopharma Holdings, Inc. | 7/9 | -2.99 | — | +43.7% |
About LIGAND PHARMACEUTICALS INC
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
FAQ
Is LGND financially healthy?
LIGAND PHARMACEUTICALS INC's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does LGND pay a dividend?
No, LIGAND PHARMACEUTICALS INC does not currently pay a dividend.
How profitable is LGND?
In FY2025, LIGAND PHARMACEUTICALS INC had a net margin of 46.4% and a return on equity of 12.2%.
Is LGND overvalued or undervalued?
LIGAND PHARMACEUTICALS INC trades at about 47.8× trailing earnings — above its 10-year norm (10-year range 1.7×–185.5×, median 24.9×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for LGND?
The average Wall-Street price target for LIGAND PHARMACEUTICALS INC is $277.60, about 5.3% below the recent price, from 10 analysts (consensus: strong buy).
Is LGND a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on LIGAND PHARMACEUTICALS INC: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone, a P/E of about 48.9×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.